Financial Toxicity for Pembrolizumab and Atezolizumab for Metastatic Non-Small Cell Lung Cancer: A Pooled Analysis of Cost-Effectiveness Analyses

Huang W, Zhu X, Weng JH, Xu K, Wang YF, Chen ZJ, Zhou Q, Liu J

Risk Management and Healthcare Policy 2025, 18:987-998

Published Date: 24 March 2025